European and North Indian Cohort of KaWasaki dIsease

Launched by MEYER CHILDREN'S HOSPITAL IRCCS · Mar 5, 2024

Keywords

ClinConnect Summary

This clinical trial is studying Kawasaki disease (KD), a condition that can cause serious heart problems in children. Researchers are trying to find better ways to identify which children are likely to be resistant to standard treatment, specifically a treatment called IVIG (intravenous immunoglobulin). While current treatments have lowered the risk of heart issues from about 25-30% to around 5%, some children still do not respond well to these treatments, which can lead to serious complications. The trial aims to see how effective different scoring systems are in predicting which patients might need more aggressive treatment right from the start.

To participate in this trial, children under 18 years old who have been diagnosed with Kawasaki disease according to specific guidelines may be eligible. However, those who do not meet the criteria for KD or have not ruled out other infections will not be included. Participants can expect to undergo assessments that help doctors understand their response to treatment and contribute to improving care for future patients with Kawasaki disease. The trial is currently recruiting participants of all genders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged less than 18 years at diagnosis
• • Diagnosis of KD according to the AHA criteria
• Exclusion Criteria:
• • Patients who do not meet the criteria for KD
• • Patients for which an alternative infectious diagnosis was not investigated and/or excluded.